세계의 동맥경화 치료제 시장 규모 조사 및 예측 : 단계별, 진단별, 치료별, 투여 경로별, 최종 사용자별, 유통 채널별, 지역별 분석(2023-2030년)

Global Atherosclerosis drugs Market is valued approximately at USD 2.7 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.16% over the forecast period 2023-2030. Atherosclerosis drugs is a therapeutic category of medications used for the treatment of atherosclerosis and related cardiovascular diseases such as heart attacks, strokes, and peripheral vascular disease. This market growth is attributed to the high consumption of cholesterol-lowering drugs by patients to reduce or avoid blockages in arteries. The increasingly fast-paced lifestyle has depleted the ordinary person's usual diet of essential nutrients that increases the risk of atherosclerosis, despite the age group and the growth rate of atherosclerosis market is the rising healthcare expenditure which helps in improving its infrastructure. The research and development in the healthcare sector have led to the production of effective atherosclerosis drugs globally.

Increasing the risk of atherosclerosis, the increased prevalence of obesity and high cholesterol is predicted to boost the market's growth rate. According to estimates from the World Health Organisation (WHO) in 2020, 40 million children under the age of five were overweight or obese. Increased consumption of food high in fat and sugar as well as an increase in physical immobility brought on by the fact that many jobs are becoming less physically demanding, changing transportation options and growing urbanization are the factors that contributes to high cholesterol rates in people that are driving the market's rapid expansion. Moreover, the market's growth is fueled by an increase in the number of research and development activities also the integration of e-Commerce and the healthcare sector will generate considerable sales potential through online pharmacies for companies in the atherosclerosis medicines market. However, Side effects of drugs and the availability of generic products are the factors expected to restrain the market growth during the forecast period.

The key regions considered for the Global Atherosclerosis drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 holding the largest market share owing to the increased frequency of atherosclerosis and technical improvement in the treatment in this region. Furthermore, increased healthcare expenditure and the presence of significant key players would drive the market development rate in this area. According to the National Centre for Chronic Disease Prevention and Health Promotion's Division for Heart Disease and Stroke Prevention, which was updated in July 2022, one person dies from cardiovascular disease every 34 seconds in the United States. Asia Pacific is expected to grow significantly during the forecast period, owing to the growing elderly population in this area and the rising level of disposable income. Additionally, the expansion of the healthcare sector's infrastructure and growing government efforts will accelerate the market's expansion in this area.

Major market player included in this report are:

• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Merck & Co
• Allergan Plc
• AstraZeneca

Recent Developments in the Market:

• In September 2022, Novo Nordisk has entered into a new strategic cooperation with Microsoft to accelerate medication research and development via the use of big data and artificial intelligence (AI). The team will employ artificial intelligence to construct models that can predict a person's risk of getting atherosclerosis or arterial plaque development. The researchers will also look for new atherosclerosis targets and indicators.
• In August 2022, AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.

Global Atherosclerosis drugs Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Stages, Diagnosis, Treatment, Route of Administration, End-Users, Distribution Channel, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
• The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Stages:

• Endothelial Damage and Immune Response
• Fatty Streak
• Plaque Growth
• Plaque Rupture

By Diagnosis:

• Ankle-brachial Index
• Doppler Ultrasound
• Echocardiogram
• Electrocardiogram
• Blood Tests
• Others

By Treatment:

• Medication
• Surgery
• Others

By Route of Administration:

• Oral,
• Parenteral
• Others

By End-Users:

• Hospitals
• Specialty Clinics
• Homecare
• Others

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Atherosclerosis drugs Market, by region, 2020-2030 (USD Billion)
  • 1.2.2. Atherosclerosis drugs Market, by Stages, 2020-2030 (USD Billion)
  • 1.2.3. Atherosclerosis drugs Market, by Diagnosis, 2020-2030 (USD Billion)
  • 1.2.4. Atherosclerosis drugs Market, by Treatment, 2020-2030 (USD Billion)
  • 1.2.5. Atherosclerosis drugs Market, by Route of Administration, 2020-2030 (USD Billion)
  • 1.2.6. Atherosclerosis drugs Market, by End-User, 2020-2030 (USD Billion)
  • 1.2.7. Atherosclerosis drugs Market, by Distribution Channel, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Atherosclerosis drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Atherosclerosis drugs Market Dynamics

• 3.1. Atherosclerosis drugs Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing investment in healthcare infrastructure
    • 3.1.1.2. Growing Geriatric Population
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost and low diagnostic rates
    • 3.1.2.2. Side effects of drugs
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Increase in the number of research and development activities
    • 3.1.3.2. Government initiatives have been essential in raising the standard of healthcare services and infrastructure

Chapter 4. Global Atherosclerosis drugs Market: Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economic
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Atherosclerosis drugs Market, by Stages

• 5.1. Market Snapshot
• 5.2. Global Atherosclerosis drugs Market by Stages, Performance - Potential Analysis
• 5.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Stages 2020-2030 (USD Billion)
• 5.4. Atherosclerosis drugs Market, Sub Segment Analysis
  • 5.4.1. Endothelial Damage and Immune Response
  • 5.4.2. Fatty Streak
  • 5.4.3. Plaque Growth
  • 5.4.4. Plaque Rupture

Chapter 6. Global Atherosclerosis drugs Market, by Diagnosis

• 6.1. Market Snapshot
• 6.2. Global Atherosclerosis drugs Market by Diagnosis, Performance - Potential Analysis
• 6.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Diagnosis 2020-2030 (USD Billion)
• 6.4. Atherosclerosis drugs Market, Sub Segment Analysis
  • 6.4.1. Ankle-brachial Index
  • 6.4.2. Doppler Ultrasound
  • 6.4.3. Echocardiogram
  • 6.4.4. Electrocardiogram
  • 6.4.5. Blood Tests
  • 6.4.6. Others

Chapter 7. Global Atherosclerosis drugs Market, by Treatment

• 7.1. Market Snapshot
• 7.2. Global Atherosclerosis drugs Market by Treatment, Performance - Potential Analysis
• 7.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Treatment 2020-2030 (USD Billion)
• 7.4. Atherosclerosis drugs Market, Sub Segment Analysis
  • 7.4.1. Medication
  • 7.4.2. Surgery
  • 7.4.3. Others

Chapter 8. Global Atherosclerosis drugs Market, by Route of Administration

• 8.1. Market Snapshot
• 8.2. Global Atherosclerosis drugs Market by Route of Administration, Performance - Potential Analysis
• 8.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
• 8.4. Atherosclerosis drugs Market, Sub Segment Analysis
  • 8.4.1. Oral
  • 8.4.2. Parenteral
  • 8.4.3. Others

Chapter 9. Global Atherosclerosis drugs Market, by End-User

• 9.1. Market Snapshot
• 9.2. Global Atherosclerosis drugs Market by End-User, Performance - Potential Analysis
• 9.3. Global Atherosclerosis drugs Market Estimates & Forecasts by End-User2020-2030 (USD Billion)
• 9.4. Atherosclerosis drugs Market, Sub Segment Analysis
  • 9.4.1. Hospitals
  • 9.4.2. Specialty Clinics
  • 9.4.3. Homecare
  • 9.4.4. Others

Chapter 10. Global Atherosclerosis drugs Market, by Distribution Channel

• 10.1. Market Snapshot
• 10.2. Global Atherosclerosis drugs Market by Distribution Channel, Performance - Potential Analysis
• 10.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
• 10.4. Atherosclerosis drugs Market, Sub Segment Analysis
  • 10.4.1. Hospital Pharmacy
  • 10.4.2. Retail Pharmacy
  • 10.4.3. Online Pharmacy
  • 10.4.4. Others

Chapter 11. Global Atherosclerosis drugs Market, Regional Analysis

• 11.1. Top Leading Countries
• 11.2. Top Emerging Countries
• 11.3. Atherosclerosis drugs Market, Regional Market Snapshot
• 11.4. North America Atherosclerosis Drugs Market
  • 11.4.1. U.S. Atherosclerosis drugs Market
    • 11.4.1.1. Stages breakdown estimates & forecasts, 2020-2030
    • 11.4.1.2. Diagnosis breakdown estimates & forecasts, 2020-2030
    • 11.4.1.3. Treatment breakdown estimates & forecasts, 2020-2030
    • 11.4.1.4. Route of Administration breakdown estimates & forecasts, 2020-2030
    • 11.4.1.5. End-User breakdown estimates & forecasts, 2020-2030
    • 11.4.1.6. Distribution Channel breakdown estimates & forecasts, 2020-2030
  • 11.4.2. Canada Atherosclerosis drugs Market
• 11.5. Europe Atherosclerosis drugs Market Snapshot
  • 11.5.1. U.K. Atherosclerosis drugs Market
  • 11.5.2. Germany Atherosclerosis drugs Market
  • 11.5.3. France Atherosclerosis drugs Market
  • 11.5.4. Spain Atherosclerosis drugs Market
  • 11.5.5. Italy Atherosclerosis drugs Market
  • 11.5.6. Rest of Europe Atherosclerosis drugs Market
• 11.6. Asia-Pacific Atherosclerosis drugs Market Snapshot
  • 11.6.1. China Atherosclerosis drugs Market
  • 11.6.2. India Atherosclerosis drugs Market
  • 11.6.3. Japan Atherosclerosis drugs Market
  • 11.6.4. Australia Atherosclerosis drugs Market
  • 11.6.5. South Korea Atherosclerosis drugs Market
  • 11.6.6. Rest of Asia Pacific Atherosclerosis Drugs Market
• 11.7. Latin America Atherosclerosis drugs Market Snapshot
  • 11.7.1. Brazil Atherosclerosis drugs Market
  • 11.7.2. Mexico Atherosclerosis drugs Market
• 11.8. Middle East & Africa Atherosclerosis drugs Market
  • 11.8.1. Saudi Arabia Atherosclerosis drugs Market
  • 11.8.2. South Africa Atherosclerosis drugs Market
  • 11.8.3. Rest of Middle East & Africa Atherosclerosis drugs Market

Chapter 12. Competitive Intelligence

• 12.1. Key Company SWOT Analysis
  • 12.1.1. Company 1
  • 12.1.2. Company 2
  • 12.1.3. Company 3
• 12.2. Top Market Strategies
• 12.3. Company Profiles
  • 12.3.1. F. Hoffmann-La Roche Ltd.
    • 12.3.1.1. Key Information
    • 12.3.1.2. Overview
    • 12.3.1.3. Financial (Subject to Data Availability)
    • 12.3.1.4. Product Summary
    • 12.3.1.5. Recent Developments
  • 12.3.2. Mylan N.V.
  • 12.3.3. Teva Pharmaceutical Industries Ltd.
  • 12.3.4. Sanofi India
  • 12.3.5. Pfizer Inc.
  • 12.3.6. GlaxoSmithKline plc
  • 12.3.7. Novartis AG
  • 12.3.8. Merck & Co
  • 12.3.9. Allergan India Pvt Ltd.
  • 12.3.10. AstraZeneca

Chapter 13. Research Process

• 13.1. Research Process
  • 13.1.1. Data Mining
  • 13.1.2. Analysis
  • 13.1.3. Market Estimation
  • 13.1.4. Validation
  • 13.1.5. Publishing
• 13.2. Research Attributes
• 13.3. Research Assumption